Condition: Migraine · Sponsor: H. Lundbeck A/S
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
This description comes directly from the study's public registry record.
Email contact via H. Lundbeck A/S · +45 36301311 · HQ_Medinfo@Lundbeck.com
Always discuss trial participation with your own doctor first.
| Yale University School of Medicine | New Haven, Connecticut, United States | Recruiting |
| Ki Health Partners LLC DBA New England Institute for Clinical Research | Stamford, Connecticut, United States | Recruiting |
| NW FL Clinical Research Group, LLC | Gulf Breeze, Florida, United States | Recruiting |
| AGA Clinical Trials - Hialeah - 4980 W 10th Ave | Hialeah, Florida, United States | Recruiting |
| Axcess Medical Research | Loxahatchee Groves, Florida, United States | Completed |
| University of South Florida | Tampa, Florida, United States | Recruiting |
| University of Kentucky | Lexington, Kentucky, United States | Recruiting |
| University of Maryland School of Medicine | Baltimore, Maryland, United States | Recruiting |
| Michigan Head Pain and Neurological Institute | Ann Arbor, Michigan, United States | Completed |
| Michigan State University - Department of Neurology | East Lansing, Michigan, United States | Completed |
| Helen Devos Childrens' Hospital - PIN | Grand Rapids, Michigan, United States | Completed |
| Dent Neurosciences Research Center Incorporated | Amherst, New York, United States | Completed |
+ 58 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05164172